Register for free
Recent Quotes
My Watchlist
Indicators
Business Insurance Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

DiaMedica Therapeutics Inc. - Common Stock (NQ:DMAC)

4.140 +0.050 (+1.22%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 6, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about DiaMedica Therapeutics Inc. - Common Stock

< Previous 1 2 3 Next >
Earnings Scheduled For May 13, 2025
Via Benzinga
Insights Ahead: DiaMedica Therapeutics's Quarterly Earnings
Via Benzinga
Why Ericsson Shares Are Trading Higher By Around 7%; Here Are 20 Stocks Moving Premarket
Via Benzinga
Earnings Scheduled For March 17, 2025
Via Benzinga
Earnings Scheduled For November 13, 2024
Via Benzinga
Preview: DiaMedica Therapeutics's Earnings
Via Benzinga
Recap: DiaMedica Therapeutics Q4 Earnings
Via Benzinga
Earnings Outlook For DiaMedica Therapeutics
Via Benzinga
This Fastenal Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday
Via Benzinga
DMAC Stock Earnings: DiaMedica Therapeutics Beats EPS for Q2 2024
DMAC stock results show that DiaMedica Therapeutics beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
DMAC Stock Earnings: DiaMedica Therapeutics Beats EPS for Q1 2024
DMAC stock results show that DiaMedica Therapeutics beat analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
DMAC Stock Earnings: DiaMedica Therapeutics Meets EPS for Q4 2023
DMAC stock results show that DiaMedica Therapeutics met analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday
Pre-market stock movers are a hot topic on Wednesday and we're offering all the details that investors need to know about this morning. 
Via InvestorPlace
Earnings Preview: DiaMedica Therapeutics
Via Benzinga
DiaMedica Therapeutics's Earnings Outlook
Via Benzinga
Earnings Scheduled For November 13, 2023
Companies Reporting Before The Bell • Sohu.com (NASDAQ:SOHU) is expected to report earnings for its third quarter. • Dixie Gr (NASDAQ:DXYN) is estimated to report earnings for its third quarter. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 22, 2023
Via Benzinga
DiaMedica Raises $37.5M Via Equity Offering, Aiding Development Activities For DM199
DiaMedica Therapeutics Inc. (NASDAQ: DMAC) has entered into an agreement with accredited investors that have agreed to provide up to $37.5 million in gross proceeds through a  
Via Benzinga
$1 Million Bet On OmniAb? Check Out These 3 Penny Stocks Insiders Are Buying
The Dow Jones closed lower by around 200 points on Thursday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or... 
Via Benzinga
Why Meta Platforms Shares Dipped Around 25%; Here Are 77 Biggest Movers From Yesterday
Gainers UserTesting, Inc. (NYSE: USER) shares jumped 91.7% to close at $7.40 after the company announced it will be acquired by Thoma Bravo and Sunstone Partners for $1.3 billion. The company also... 
Via Benzinga
Why Cyclerion Therapeutics Shares Traded Lower By Around 38%; Here Are 70 Biggest Movers From Yesterday
Gainers Green Giant Inc. (NASDAQ: GGE) jumped 161.1% to close at $1.88 after dipping 29% on Wednesday. 
Via Benzinga
DiaMedica Therapeutics: Q2 Earnings Insights
  DiaMedica Therapeutics (NASDAQ:DMAC) reported its Q2 earnings results on Wednesday, August 10, 2022 at 04:30 PM. Here's what investors need to know about the announcement. 
Via Benzinga
Why Revelation Biosciences Shares Are Trading Higher By 29%, Here Are 50 Stocks Moving In Thursday's Mid-Day Session
Gainers Statera Biopharma, Inc. (NASDAQ: STAB) rose 98% to $0.2777. Statera Biopharma was recently granted European patent number EP3206708 titled "Methods And Compositions For The Treatment Of... 
Via Benzinga
Biotech Daily: Cancer Causing Impurities In Merck's Diabetic Drug, Vir Bio-GSK Shun FDA Submission Plans For COVID-19 Treatment, Aethlon's Monkeypox Trial
Here's a roundup of top developments in the biotech space over the last 24 hours: 
Via Benzinga
DiaMedica Therapeutics Earnings Preview
  DiaMedica Therapeutics (NASDAQ:DMAC) is set to give its latest quarterly earnings report on Wednesday, 2022-08-10. Here's what investors need to know before the announcement. 
Via Benzinga
3 Penny Stocks Insiders Are Buying: DiaMedica Therapeutics, Troika Media And More
U.S. stock futures traded lower this morning on Friday. Investors, meanwhile, focused on some notable insider trades. When insiders purchase or sell shares, it indicates their confidence or concern... 
Via Benzinga
This Low-Float Stock Jumps Around 148%; Here's 64 Biggest Movers From Yesterday
Gainers United Maritime Corporation (NASDAQ: USEA) climbed 147.6% to close at $7.08 on Thursday on heavy momentum following the company's recent listing on the Nasdaq Capital Market. 
Via Benzinga
Nasdaq Surges 250 Points; Crude Oil Rises Sharply
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite jumping 250 points following the release of data on initial jobless claims. 
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
Thursday's session saw 49 companies set new 52-week lows. 
Via Benzinga
Dow Jumps More Than 200 Points; Samsung Sees This Much Surge In Quarterly Revenue
U.S. stocks traded higher midway through trading, with the Dow Jones jumping more than 200 points following the release of data on initial jobless claims. 
Via Benzinga
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Business Insurance is a singular, authoritative news and information source for executives focused upon risk management, risk transfer and risk financing.

Never miss important news. Subscribe to our newsletter.
Register for free

Information

Copyright 2024. BUSINESS INSURANCE HOLDINGS